KIT and melanoma: Several other c-Kit inhibitors, including sunitinib [9], dasatinib [11] and nilotinib [12] are active in c-Kit mutated melanoma, but their inhibitory profile varies and comparisons with imatinib are difficult due to the small numbers of reported patients on alternative kinase inhibitors.